ArticleTranslational lung cancer research2025
Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage.
Mylène Wespiser et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.